The Community Guide

- gsearch

Search Results

Narrow Results:

2021 2
2020 5
2019 7
2018 3

1 - 17 of 17 Results

Refine Results

Refine Results:

MenAfriNet: A Network Supporting Case-Based Meningitis Surveillance and Vaccine Evaluation in the Meningitis Belt of Africa

CITE Title : MenAfriNet: A Network Supporting Case-Based Meningitis Surveillance and Vaccine Evaluation in the Meningitis Belt of Africa Personal Author(s) : Patel, Jaymin C.;Soeters, Heidi M.;Diallo, Alpha Oumar;Bicaba, Brice W.;Kadadé, Goumbi;Dembélé, Assétou Y.;Acyl, Mahamat A.;Nikiema, Christelle;Lingani, Clement;Hatcher, Cynthia;Acosta, Anna M.;Thomas, Jennifer D.;Diomande, Fabien;Martin, Stacey;Clark, Thomas A.;Mihigo, Richard;Hajjeh, Rana A.;Zilber, Catherine H.;Aké, Flavien;Mbaeyi, Sarah A.;Wang, Xin;Moisi, Jennifer C.;Ronveaux, Olivier;Mwenda, Jason M.;Novak, Ryan T.; Published Date : Oct 31 2019 Source : J Infect Dis. 220(Suppl 4):S148-S154 URL : https://stacks.cdc.gov/view/cdc/83238 Patel, Jaymin C. et al. (2019). MenAfriNet: A Network Supporting Case-Based Meningitis Surveillance and Vaccine Evaluation in the Meningitis Belt of Africa. 220 Patel, Jaymin C. et al. "MenAfriNet: A Network Supporting Case-Based Meningitis Surveillance and Vaccine Evaluation in the Meningitis Belt of Africa" 220 (2019) Patel, Jaymin C. et al. "MenAfriNet: A Network Supporting Case-Based Meningitis Surveillance and Vaccine Evaluation in the Meningitis Belt of Africa" vol. 220, 2019 Export RIS Citation Information.

:

Patel, Jaymin C. ;

Soeters, Heidi M.

Oct 31 2019 | J Infect Dis. 220(Suppl 4):S148-S154

:

Meningococcal meningitis remains a significant public health threat, especially in the African meningitis belt where Neisseria meningitidis serogroup ...
Initial validation of a simulation model for estimating the impact of serogroup A Neisseria meningitidis vaccination in the African meningitis belt

CITE Title : Initial validation of a simulation model for estimating the impact of serogroup A Neisseria meningitidis vaccination in the African meningitis belt Personal Author(s) : Jackson, Michael L.;Diallo, Alpha Oumar;Médah, Isaie;Bicaba, Brice Wilfried;Yaméogo, Issaka;Koussoubé, Daouda;Ouédraogo, Rasmata;Sangaré, Lassané;Mbaeyi, Sarah A.; Published Date : Oct 25 2018 Source : PLoS One. 13(10). URL : https://stacks.cdc.gov/view/cdc/60849 Jackson, Michael L. et al. (2018). Initial validation of a simulation model for estimating the impact of serogroup A Neisseria meningitidis vaccination in the African meningitis belt. 13(10). Jackson, Michael L. et al. "Initial validation of a simulation model for estimating the impact of serogroup A Neisseria meningitidis vaccination in the African meningitis belt" 13, no. 10 (2018) Jackson, Michael L. et al. "Initial validation of a simulation model for estimating the impact of serogroup A Neisseria meningitidis vaccination in the African meningitis belt" vol. 13, no. 10, 2018 Export RIS Citation Information.

:

Jackson, Michael L. ;

Diallo, Alpha Oumar

Oct 25 2018 | PLoS One. 13(10).

:

We previously developed a mathematical simulation of serogroup A Neisseria meningitidis (NmA) transmission in Burkina Faso, with the goal of forecasti...
University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013–2018

CITE Title : University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013–2018 Personal Author(s) : Soeters, Heidi M.;McNamara, Lucy A.;Blain, Amy E.;Whaley, Melissa;MacNeil, Jessica R.;Hariri, Susan;Mbaeyi, Sarah A.; Corporate Authors(s) : for the Serogroup B Meningococcal Disease University Outbreak Group Published Date : Mar 2019 Source : Emerg Infect Dis. 25(3):434-440 URL : https://stacks.cdc.gov/view/cdc/76662 Soeters, Heidi M. et al. (2019). University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013–2018. 25(3). Soeters, Heidi M. et al. "University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013–2018" 25, no. 3 (2019) Soeters, Heidi M. et al. "University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013–2018" vol. 25, no. 3, 2019 Export RIS Citation Information.

:

Soeters, Heidi M. ;

McNamara, Lucy A.

Mar 2019 | Emerg Infect Dis. 25(3):434-440

:

We reviewed university-based outbreaks of meningococcal disease caused by serogroup B and vaccination responses in the United States in the years foll...
Use of Pfizer-BioNTech COVID-19 vaccine : clinical considerations

CITE Title : Use of Pfizer-BioNTech COVID-19 vaccine : clinical considerations Personal Author(s) : Mbaeyi, Sarah A. Corporate Authors(s) : United States. Advisory Committee on Immunization Practices. COVID-19 Vaccines Work Group. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2020 December 11-12, 2020 : Atlanta, GA) Published Date : December 12, 2020 Series : ACIP meeting COVID-19 Vaccines URL : https://stacks.cdc.gov/view/cdc/105436 Mbaeyi, Sarah A. (2020). Use of Pfizer-BioNTech COVID-19 vaccine : clinical considerations. 2000211(020103). Mbaeyi, Sarah A. "Use of Pfizer-BioNTech COVID-19 vaccine : clinical considerations" 2000211, no. 020103 (2020) Mbaeyi, Sarah A. "Use of Pfizer-BioNTech COVID-19 vaccine : clinical considerations" vol. 2000211, no. 020103, 2020 Export RIS Citation Information.

:

Mbaeyi, Sarah A.

December 12, 2020 | ACIP meeting COVID-19 Vaccines

:

COVID-03-Mbaeyi-508.pdf
Use of mRNA COVID-19 vaccines : interim clinical considerations

CITE Title : Use of mRNA COVID-19 vaccines : interim clinical considerations Personal Author(s) : Mbaeyi, Sarah A. Corporate Authors(s) : United States. Advisory Committee on Immunization Practices. COVID-19 Vaccines Work Group. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2020 December 19-20, 2020 : Atlanta, GA) Published Date : December 19, 2020 Series : ACIP meeting COVID-19 Vaccines URL : https://stacks.cdc.gov/view/cdc/105482 Mbaeyi, Sarah A. (2020). Use of mRNA COVID-19 vaccines : interim clinical considerations. 2000212(0100106). Mbaeyi, Sarah A. "Use of mRNA COVID-19 vaccines : interim clinical considerations" 2000212, no. 0100106 (2020) Mbaeyi, Sarah A. "Use of mRNA COVID-19 vaccines : interim clinical considerations" vol. 2000212, no. 0100106, 2020 Export RIS Citation Information.

:

Mbaeyi, Sarah A.

December 19, 2020 | ACIP meeting COVID-19 Vaccines

:

06-COVID-Mbaeyi-508.pdf
Current ACIP recommendations for MenB vaccines

CITE Title : Current ACIP recommendations for MenB vaccines Personal Author(s) : Mbaeyi, Sarah A.;Whitlatch, Frank; Corporate Authors(s) : United States. Advisory Committee on Immunization Practices. Meningococcal Work Group.;National Center for Immunization and Respiratory Diseases (U.S.). Immunization Services Division.; Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2019 June 26-27, 2019 : Atlanta, GA) Published Date : June 27, 2019 Series : ACIP meeting Meningococcal Vaccines URL : https://stacks.cdc.gov/view/cdc/80763 Mbaeyi, Sarah A. and Whitlatch, Frank (2019). Current ACIP recommendations for MenB vaccines. 201902(020303). Mbaeyi, Sarah A. and Whitlatch, Frank "Current ACIP recommendations for MenB vaccines" 201902, no. 020303 (2019) Mbaeyi, Sarah A. and Whitlatch, Frank "Current ACIP recommendations for MenB vaccines" vol. 201902, no. 020303, 2019 Export RIS Citation Information.

:

Mbaeyi, Sarah A. ;

Whitlatch, Frank

June 27, 2019 | ACIP meeting Meningococcal Vaccines

:

Meningococcal-2b-508.pdf
Serogroup B meningococcal vaccine booster doses

CITE Title : Serogroup B meningococcal vaccine booster doses Personal Author(s) : Mbaeyi, Sarah A. Corporate Authors(s) : United States. Advisory Committee on Immunization Practices. Meningococcal Work Group. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2019 June 26-27, 2019 : Atlanta, GA) Published Date : June 27, 2019 Series : ACIP meeting Meningococcal Vaccines URL : https://stacks.cdc.gov/view/cdc/80762 Mbaeyi, Sarah A. (2019). Serogroup B meningococcal vaccine booster doses. 201902(020302). Mbaeyi, Sarah A. "Serogroup B meningococcal vaccine booster doses" 201902, no. 020302 (2019) Mbaeyi, Sarah A. "Serogroup B meningococcal vaccine booster doses" vol. 201902, no. 020302, 2019 Export RIS Citation Information.

:

Mbaeyi, Sarah A.

June 27, 2019 | ACIP meeting Meningococcal Vaccines

:

Meningococcal-2-Mbaeyi-508.pdf
Considerations for COVID-19 vaccine prioritization

CITE Title : Considerations for COVID-19 vaccine prioritization Personal Author(s) : Mbaeyi, Sarah A. Corporate Authors(s) : United States. Advisory Committee on Immunization Practices. COVID-19 Vaccines Work Group. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2020 June 24 : Atlanta, GA) Published Date : June 24, 2020 Series : ACIP meeting COVID-19 Vaccines URL : https://stacks.cdc.gov/view/cdc/91109 Mbaeyi, Sarah A. (2020). Considerations for COVID-19 vaccine prioritization. 202002(010404). Mbaeyi, Sarah A. "Considerations for COVID-19 vaccine prioritization" 202002, no. 010404 (2020) Mbaeyi, Sarah A. "Considerations for COVID-19 vaccine prioritization" vol. 202002, no. 010404, 2020 Export RIS Citation Information.

:

Mbaeyi, Sarah A.

June 24, 2020 | ACIP meeting COVID-19 Vaccines

:

COVID-08-Mbaey-508.pdf
Updated ACIP statement for meningococcal vaccination in the United States

CITE Title : Updated ACIP statement for meningococcal vaccination in the United States Personal Author(s) : Mbaeyi, Sarah A. Corporate Authors(s) : United States. Advisory Committee on Immunization Practices. Meningococcal Work Group. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2019 June 26-27, 2019 : Atlanta, GA) Published Date : June 27, 2019 Series : ACIP meeting Meningococcal Vaccines URL : https://stacks.cdc.gov/view/cdc/80764 Mbaeyi, Sarah A. (2019). Updated ACIP statement for meningococcal vaccination in the United States. 201902(020304). Mbaeyi, Sarah A. "Updated ACIP statement for meningococcal vaccination in the United States" 201902, no. 020304 (2019) Mbaeyi, Sarah A. "Updated ACIP statement for meningococcal vaccination in the United States" vol. 201902, no. 020304, 2019 Export RIS Citation Information.

:

Mbaeyi, Sarah A.

June 27, 2019 | ACIP meeting Meningococcal Vaccines

:

Meningococcal-3-Mbaeyi-508.pdf
Serogroup B meningococcal vaccines booster doses : Work Group interpretation, considerations for policy options, and next steps

CITE Title : Serogroup B meningococcal vaccines booster doses : Work Group interpretation, considerations for policy options, and next steps Personal Author(s) : Mbaeyi, Sarah A. Corporate Authors(s) : United States. Advisory Committee on Immunization Practices. Meningococcal Work Group. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2019 February 27-28 : Atlanta, GA) Published Date : February 28, 2019 Series : ACIP meeting Meningococcal Vaccines URL : https://stacks.cdc.gov/view/cdc/78097 Mbaeyi, Sarah A. (2019). Serogroup B meningococcal vaccines booster doses : Work Group interpretation, considerations for policy options, and next steps. 201901(020305). Mbaeyi, Sarah A. "Serogroup B meningococcal vaccines booster doses : Work Group interpretation, considerations for policy options, and next steps" 201901, no. 020305 (2019) Mbaeyi, Sarah A. "Serogroup B meningococcal vaccines booster doses : Work Group interpretation, considerations for policy options, and next steps" vol. 201901, no. 020305, 2019 Export RIS Citation Information.

:

Mbaeyi, Sarah A.

February 28, 2019 | ACIP meeting Meningococcal Vaccines

:

Meningococcal-5-Mbaeyi-508.pdf
COVID-19 vaccines : update on allergic reactions, contraindications, and precautions

CITE Title : COVID-19 vaccines : update on allergic reactions, contraindications, and precautions Personal Author(s) : Shimabukuro, Tom T.;Mbaeyi, Sarah A.; Corporate Authors(s) : National Center for Preparedness, Detection, and Control of Infectious Diseases (U.S.). Clinician Outreach and Communication Activity.;CDC COVID-19 Response Team.; Published Date : December 30, 2020 Pages in Document : 36 numbered slides Series : Clinician Outreach and Communication Activity (COCA) Webinar URL : https://stacks.cdc.gov/view/cdc/99850 Shimabukuro, Tom T. and Mbaeyi, Sarah A. (2020). COVID-19 vaccines : update on allergic reactions, contraindications, and precautions. Shimabukuro, Tom T. and Mbaeyi, Sarah A. "COVID-19 vaccines : update on allergic reactions, contraindications, and precautions" (2020) Shimabukuro, Tom T. and Mbaeyi, Sarah A. "COVID-19 vaccines : update on allergic reactions, contraindications, and precautions" , 2020 Export RIS Citation Information.

:

Shimabukuro, Tom T. ;

Mbaeyi, Sarah A.

December 30, 2020 | Clinician Outreach and Communication Activity (COCA) Webinar

:

Date: Wednesday, December 30, 2020Time: 2:00 PM – 3:00 PM ETDuring this COCA call, clinicians will give an overview of recommendations for use of CO...
Bacterial meningitis epidemiology in 5 countries in the meningitis belt of sub-Saharan Africa, 2015–2017

CITE Title : Bacterial meningitis epidemiology in 5 countries in the meningitis belt of sub-Saharan Africa, 2015–2017 Personal Author(s) : Soeters, Heidi M.;Diallo, Alpha Oumar;Bicaba, Brice W.;Kadadé, Goumbi;Dembélé, Assétou Y.;Acyl, Mahamat A.;Nikiema, Christelle;Sadji, Adodo Yao;Poy, Alain N.;Lingani, Clement;Tall, Haoua;Sakandé, Souleymane;Tarbangdo, Félix;Aké, Flavien;Mbaeyi, Sarah A.;Moïsi, Jennifer;Paye, Marietou F.;Sanogo, Yibayiri Osee;Vuong, Jeni T.;Wang, Xin;Ronveaux, Olivier;Novak, Ryan T.; Corporate Authors(s) : MenAfriNet Consortium Published Date : 10 31 2019;10-31-; Source : J Infect Dis. 220(Suppl 4):S165-S174 URL : https://stacks.cdc.gov/view/cdc/83239 Soeters, Heidi M. et al. (2019). Bacterial meningitis epidemiology in 5 countries in the meningitis belt of sub-Saharan Africa, 2015–2017. 220 Soeters, Heidi M. et al. "Bacterial meningitis epidemiology in 5 countries in the meningitis belt of sub-Saharan Africa, 2015–2017" 220 (2019) Soeters, Heidi M. et al. "Bacterial meningitis epidemiology in 5 countries in the meningitis belt of sub-Saharan Africa, 2015–2017" vol. 220, 2019 Export RIS Citation Information.

:

Soeters, Heidi M. ;

Diallo, Alpha Oumar

10 31 2019 | J Infect Dis. 220(Suppl 4):S165-S174

:

Background:The MenAfriNet Consortium supports strategic implementation of case-based meningitis surveillance in key high-risk countries of the African...
Meningococcal Disease Surveillance in Men Who Have Sex with Men — United States, 2015–2016

CITE Title : Meningococcal Disease Surveillance in Men Who Have Sex with Men — United States, 2015–2016 Personal Author(s) : Bozio, Catherine H.;Blain, Amy;MacNeil, Jessica;Retchless, Adam;Weil, Lauren M.;Wang, Xin;Jenkins, Laurel T.;Rodriguez-Rivera, Lorraine D.;Jarashow, Claire;Ngo, Van;Hariri, Susan;Mbaeyi, Sarah A.;Oliver, Sara E.; Published Date : Sep 28 2018 Pages in Document : 4 pdf pages Series : Weekly Report: Morbidity and Mortality Weekly Report (MMWR) Source : MMWR Morbidity Mortal Weekly Rep. 67(38):1060-1063. DOI : http://dx.doi.org/10.15585/mmwr.mm6738a4 Journal Title : Morbidity and Mortality Weekly Report (MMWR) Bozio, Catherine H. et al. (2018). Meningococcal Disease Surveillance in Men Who Have Sex with Men — United States, 2015–2016. 67(38). http://dx.doi.org/10.15585/mmwr.mm6738a4 Bozio, Catherine H. et al. "Meningococcal Disease Surveillance in Men Who Have Sex with Men — United States, 2015–2016" 67, no. 38 (2018), http://dx.doi.org/10.15585/mmwr.mm6738a4 Bozio, Catherine H. et al. "Meningococcal Disease Surveillance in Men Who Have Sex with Men — United States, 2015–2016" vol. 67, no. 38, 2018, http://dx.doi.org/10.15585/mmwr.mm6738a4 Export RIS Citation Information.

:

Bozio, Catherine H. ;

Blain, Amy

Sep 28 2018 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)

:

Meningococcal disease is a rare, but serious, bacterial infection that progresses rapidly and can be life-threatening, even with prompt antibiotic tre...
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021

CITE Title : Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021 Personal Author(s) : Rosenblum, Hannah G.;Hadler, Stephen C.;Moulia, Danielle;Shimabukuro, Tom T.;Su, John R.;Tepper, Naomi K.;Ess, Kevin C.;Woo, Emily Jane;Mba-Jonas, Adamma;Alimchandani, Meghna;Nair, Narayan;Klein, Nicola P.;Hanson, Kayla E.;Markowitz, Lauri E.;Wharton, Melinda;McNally, Veronica V.;Romero, José R.;Talbot, H. Keipp;Lee, Grace M.;Daley, Matthew F.;Mbaeyi, Sarah A.;Oliver, Sara E.; Published Date : 8 13 2021 Pages in Document : 6 pdf pages Series : Weekly Report: Morbidity and Mortality Weekly Report (MMWR) Source : MMWR Morbidity Mortal Weekly Rep. 70(32):1094-1099 DOI : http://dx.doi.org/10.15585/mmwr.mm7032e4 Journal Title : Morbidity and Mortality Weekly Report (MMWR) Rosenblum, Hannah G. et al. (2021). Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021. 70(32). http://dx.doi.org/10.15585/mmwr.mm7032e4 Rosenblum, Hannah G. et al. "Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021" 70, no. 32 (2021), http://dx.doi.org/10.15585/mmwr.mm7032e4 Rosenblum, Hannah G. et al. "Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021" vol. 70, no. 32, 2021, http://dx.doi.org/10.15585/mmwr.mm7032e4 Export RIS Citation Information.

:

Rosenblum, Hannah G. ;

Hadler, Stephen C.

8 13 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)

:

In December 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for Pfizer-BioNTech and Moderna Covid-19 Vaccines,...
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2017

CITE Title : National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2017 Personal Author(s) : Walker, Tanja Y.;Elam-Evans, Laurie D.;Yankey, David;Markowitz, Lauri E.;Williams, Charnetta L.;Mbaeyi, Sarah A.;Fredua, Benjamin;Stokley, Shannon; Corporate Authors(s) : United States. Advisory Committee on Immunization Practices. Published Date : Aug 24 2018 Pages in Document : 9 pdf pages Series : Weekly Report: Morbidity and Mortality Weekly Report (MMWR) Source : MMWR Morbidity Mortal Weekly Rep. 67(33):909-917. DOI : http://dx.doi.org/10.15585/mmwr.mm6733a1 Journal Title : Morbidity and Mortality Weekly Report (MMWR) Walker, Tanja Y. et al. (2018). National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2017. 67(33). http://dx.doi.org/10.15585/mmwr.mm6733a1 Walker, Tanja Y. et al. "National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2017" 67, no. 33 (2018), http://dx.doi.org/10.15585/mmwr.mm6733a1 Walker, Tanja Y. et al. "National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2017" vol. 67, no. 33, 2018, http://dx.doi.org/10.15585/mmwr.mm6733a1 Export RIS Citation Information.

:

Walker, Tanja Y. ;

Elam-Evans, Laurie D.

Aug 24 2018 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)

:

The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of persons aged 11-12 years with human papillomavirus (HPV) vac...
Meningococcal vaccination : recommendations of the Advisory Committee on Immunization Practices, United States, 2020

CITE Title : Meningococcal vaccination : recommendations of the Advisory Committee on Immunization Practices, United States, 2020 Personal Author(s) : Mbaeyi, Sarah A.;Bozio, Catherine H.;Duffy, Jonathan;Rubin, Lorry G.;Hariri, Susan;Stephens, David S.;MacNeil, Jessica R.; Corporate Authors(s) : United States. Advisory Committee on Immunization Practices.;National Center for Immunization and Respiratory Diseases (U.S.). Division of Bacterial Diseases.;National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Immunization Safety Office.; Published Date : September 25 2020 Pages in Document : 41 pdf page Series : Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR) Source : MMWR Recomm Rep. 69(9):1-41 URL : https://stacks.cdc.gov/view/cdc/95034 Journal Title : Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports Mbaeyi, Sarah A. et al. (2020). Meningococcal vaccination : recommendations of the Advisory Committee on Immunization Practices, United States, 2020. 69(9). Mbaeyi, Sarah A. et al. "Meningococcal vaccination : recommendations of the Advisory Committee on Immunization Practices, United States, 2020" 69, no. 9 (2020) Mbaeyi, Sarah A. et al. "Meningococcal vaccination : recommendations of the Advisory Committee on Immunization Practices, United States, 2020" vol. 69, no. 9, 2020 Export RIS Citation Information.

:

Mbaeyi, Sarah A. ;

Bozio, Catherine H.

September 25 2020 | Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR)

:

This report compiles and summarizes all recommendations from CDC’s Advisory Committee on Immunization Practices (ACIP) for use of meningococcal vacc...
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and MRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update From the Advisory Committee on Immunization Practices — United States, July 2021

CITE Title : Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and MRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update From the Advisory Committee on Immunization Practices — United States, July 2021 Personal Author(s) : Rosenblum, Hannah G.;Hadler, Stephen C.;Moulia, Danielle;Shimabukuro, Tom T.;Su, John R.;Tepper, Naomi K.;Ess, Kevin C.;Woo, Emily Jane;Mba-Jonas, Adamma;Alimchandani, Meghna;Nair, Narayan;Klein, Nicola P.;Hanson, Kayla E.;Markowitz, Lauri E.;Wharton, Melinda;McNally, Veronica V.;Romero, José R.;Talbot, H. Keipp;Lee, Grace M.;Daley, Matthew F.;Mbaeyi, Sarah A.;Oliver, Sara E.; Corporate Authors(s) : United States. Advisory Committee on Immunization Practices.;CDC COVID-19 Response Team.;Centers for Disease Control and Prevention (U.S.). Epidemic Intelligence Service.;Vanderbilt University School of Medicine.;United States. Food and Drug Administration.;Kaiser Permanente Northern California. Division of Research.;Marshfield Clinic Research Institute.;Franny Strong Foundation (West Bloomfield, Michigan);Arkansas. Department of Arkansas. Department of Health.;Stanford University School of Medicine.;Kaiser Permanente Colorado. Institute for Health Research.; Published Date : August 10, 2021 Pages in Document : 7 pdf pages Series : Weekly Report: Morbidity and Mortality Weekly Report (MMWR) Source : MMWR: Morbidity and Mortality Weekly Report 2021; v. 70 Early Release URL : https://stacks.cdc.gov/view/cdc/108729 Rosenblum, Hannah G. et al. (2021). Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and MRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update From the Advisory Committee on Immunization Practices — United States, July 2021. 70 Rosenblum, Hannah G. et al. "Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and MRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update From the Advisory Committee on Immunization Practices — United States, July 2021" 70 (2021) Rosenblum, Hannah G. et al. "Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and MRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update From the Advisory Committee on Immunization Practices — United States, July 2021" vol. 70, 2021 Export RIS Citation Information.

:

Rosenblum, Hannah G. ;

Hadler, Stephen C.

August 10, 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)

:

What is already known about this topic? Rare serious adverse events have been reported after COVID-19 vaccination, including Guillain-Barré syndrome ...